The effect of tranexamic acid on the quality of life and blood loss of women with menorrhagia: A clinical trial

Heavy menstrual bleeding is one of the leading causes of poor quality of life and iron deficiency anemia in women of reproductive age. This study was conducted to investigate the therapeutic effect of tranexamic acid (TA) on menorrhagia.

In this before and after clinical trial, 46 women with menorrhagia were selected and, after a control cycle for evaluation of the volume and duration of primary bleeding, were subjected to tranexamic acid treatment (500mg every 6 hours from day 1 to 5 of bleeding) for 3 consecutive cycles. Data on the duration of bleeding, amount of bleeding (PBAC chart), quality of life (SF-36 and MQ questionnaires), and hemoglobin and ferritin values were checked and compared before and after treatment using SPSS software.

Tranexamic acid reduced mean PBAC score from 242.86 (160.47) in control cycle to 101.50 (72.67) after the third cycle (p<0.001). Hemoglobin increased from 11.85 (0.84) to 13.08 (0.97) g/dl and ferritin increased from 15.9 (20.39) to 22.13 (2.03) ng/dl (p<0.001). Duration of menstrual bleeding decreased from 7.6 (1.23) days to 6.86 (0.84) days (p=0.001). Tranexamic acid reduced mean MQ score from 70.26 (17.64) to 11.64 (6.49) (p<0.0001). Quality of life scores increased in all aspects (except for bodily pain scale) (p<0.001).

TA due to its short course of prescription, fewer side effects, especially on the pattern of bleeding and menstrual cycle, and not having hormonal effects, seems to be an effective drug for menorrhagia in women of reproductive age.